ConductScience.org, home

Paper42657161

Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.

Alasheev AY and 3 others. Front Oncol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. Papers, record 42657161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42657161

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.
PubMed
Journal
Front Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-17
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alasheev AYAnton Yu
2Hamama RRaneem
3Petersen EVElena V
4Maximov PYPhilipp Y

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in42889272Correction: Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.https://conductscience.org/library/papers/42889272

Source PubMed

Download CSV of comments and corrections

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137657462
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol2023https://conductscience.org/library/papers/37657462PubMed
238572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
338819400Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.Clin Cancer Res2024https://conductscience.org/library/papers/38819400PubMed
440702893NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders.J Med Chem2025https://conductscience.org/library/papers/40702893PubMed
535642432Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.Mol Cancer Ther2022https://conductscience.org/library/papers/35642432PubMed
637377342Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.J Med Chem2023https://conductscience.org/library/papers/37377342PubMed
738811701Innovative cancer therapies offer new hope.Nature2024https://conductscience.org/library/papers/38811701PubMed
820855825Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.J Clin Oncol2010https://conductscience.org/library/papers/20855825PubMed
937348019
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
J Clin Oncol2023https://conductscience.org/library/papers/37348019PubMed
1036224343Molecular targeted therapy for anticancer treatment.Exp Mol Med2022https://conductscience.org/library/papers/36224343PubMed
1120824023Endocrine Therapy - What Else?Breast Care (Basel)2008https://conductscience.org/library/papers/20824023PubMed
1231630379Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.Drugs2019https://conductscience.org/library/papers/31630379PubMed
1339660834Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.N Engl J Med2025https://conductscience.org/library/papers/39660834PubMed
1437258523Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.NPJ Breast Cancer2023https://conductscience.org/library/papers/37258523PubMed
154167125The results of adrenalectomy in advanced breast cancer in 500 consecutive patients.Surg Gynecol Obstet1967https://conductscience.org/library/papers/4167125PubMed
1627908454Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.Lancet2016https://conductscience.org/library/papers/27908454PubMed
1734028522The physiological role of estrogen receptor functional domains.Essays Biochem2021https://conductscience.org/library/papers/34028522PubMed
189747868Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst1998https://conductscience.org/library/papers/9747868PubMed
1920404000Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.Cancer Prev Res (Phila)2010https://conductscience.org/library/papers/20404000PubMed
2015894097Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet2005https://conductscience.org/library/papers/15894097PubMed

See all 41 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42970051Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer.Med Chem Res2026https://conductscience.org/library/papers/42970051

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
PIK3CB5291PubTator's text mininghttps://conductscience.org/library/genes/5291NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42657161

GET https://conductscience.org/api/papers/v1/42657161/references?page=2